Novartis Investigative Site

Haseki Istanbul 34096

0 studies enrolling now · 6 studies all time

What they study most

Heart Failure With Reduced Ejection Fraction, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Scelrosis, Relapsing Remitting Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) — Completed
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early